Published in Biochim Biophys Acta on June 03, 2016
Allosteric control of antibody-prion recognition through oxidation of a disulfide bond between the CH and CL chains. Protein Eng Des Sel (2016) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Protein folding and misfolding. Nature (2003) 14.92
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A (2005) 8.60
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci (2003) 8.44
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol (2004) 4.63
Conformational disease. Lancet (1997) 4.53
Folding funnels, binding funnels, and protein function. Protein Sci (1999) 4.22
Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res (2002) 3.79
Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci (2000) 3.74
Persistence of native-like topology in a denatured protein in 8 M urea. Science (2001) 3.38
Folding funnels and binding mechanisms. Protein Eng (1999) 3.25
From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q Rev Biophys (1998) 3.04
The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol (2014) 2.99
Amyloidosis. Annu Rev Biochem (1992) 2.78
Atomic-level characterization of disordered protein ensembles. Curr Opin Struct Biol (2007) 2.65
Folding and binding cascades: shifts in energy landscapes. Proc Natl Acad Sci U S A (1999) 2.37
Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett (2004) 2.16
Extended disordered proteins: targeting function with less scaffold. Trends Biochem Sci (2003) 2.12
Amyloid beta-protein monomer structure: a computational and experimental study. Protein Sci (2006) 1.99
Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape. Chem Rev (2010) 1.62
Aβ(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. Nat Struct Mol Biol (2015) 1.42
Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biol Chem (2005) 1.40
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis (2012) 1.39
Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener (2013) 1.35
Zinc ions promote Alzheimer Abeta aggregation via population shift of polymorphic states. Proc Natl Acad Sci U S A (2010) 1.32
Insight into the PrPC-->PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants. Proc Natl Acad Sci U S A (2004) 1.31
Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci U S A (2009) 1.29
Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 1.26
Surface structure of amyloid-beta fibrils contributes to cytotoxicity. Biochemistry (2007) 1.23
Similarities between the spectrin SH3 domain denatured state and its folding transition state. J Mol Biol (2000) 1.18
Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol (2008) 1.17
Structural biology: Breaking the protein rules. Nature (2011) 1.09
Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J Mol Biol (2010) 1.09
The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem (1996) 1.07
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep (2013) 1.02
Antibody binding defines a structure for an epitope that participates in the PrPC-->PrPSc conformational change. J Mol Biol (1999) 1.00
Minimal Zn(2+) binding site of amyloid-β. Biophys J (2010) 0.99
Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev (2014) 0.98
An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition. J Biol Chem (2012) 0.96
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Curr Opin Psychiatry (2014) 0.96
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem (2009) 0.94
Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme. Proc Natl Acad Sci U S A (2013) 0.94
Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. J Mol Biol (2010) 0.94
Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment. Proc Natl Acad Sci U S A (2012) 0.91
Conformational basis for asymmetric seeding barrier in filaments of three- and four-repeat tau. J Am Chem Soc (2012) 0.91
Polymorphic triple beta-sheet structures contribute to amide hydrogen/deuterium (H/D) exchange protection in the Alzheimer amyloid beta42 peptide. J Biol Chem (2011) 0.91
Polymorphic C-terminal beta-sheet interactions determine the formation of fibril or amyloid beta-derived diffusible ligand-like globulomer for the Alzheimer Abeta42 dodecamer. J Biol Chem (2010) 0.90
Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol (2011) 0.88
Probing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobody. J Am Chem Soc (2014) 0.87
Introduction to intrinsically disordered proteins (IDPs). Chem Rev (2014) 0.87
Cross-seeding and conformational selection between three- and four-repeat human Tau proteins. J Biol Chem (2012) 0.87
Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1. Acta Crystallogr D Biol Crystallogr (2012) 0.87
Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10. Hum Mol Genet (2013) 0.86
Protein Ensembles: How Does Nature Harness Thermodynamic Fluctuations for Life? The Diverse Functional Roles of Conformational Ensembles in the Cell. Chem Rev (2016) 0.86
Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res Ther (2014) 0.84
Antibodies and protein misfolding: From structural research tools to therapeutic strategies. Biochim Biophys Acta (2014) 0.84
X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease. FEBS Lett (2007) 0.84
Estimation of interdomain flexibility of N-terminus of factor H using residual dipolar couplings. Biochemistry (2011) 0.83
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies. Sci Rep (2015) 0.83
Bound water at protein-protein interfaces: partners, roles and hydrophobic bubbles as a conserved motif. PLoS One (2011) 0.83
Structural Insight into Tau Protein's Paradox of Intrinsically Disordered Behavior, Self-Acetylation Activity, and Aggregation. J Phys Chem Lett (2014) 0.82
Structures of Abeta-related peptide--monoclonal antibody complexes. Biochemistry (2009) 0.82
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther (2014) 0.82
Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol (2013) 0.81
Monoclonal antibody MN423 as a stable mold facilitates structure determination of disordered tau protein. J Struct Biol (2010) 0.80
Determination of the individual roles of the linker residues in the interdomain motions of calmodulin using NMR chemical shifts. J Mol Biol (2014) 0.79
Prion protein-specific antibodies-development, modes of action and therapeutics application. Viruses (2014) 0.78
Interaction between bound water molecules and local protein structures: A statistical analysis of the hydrogen bond structures around bound water molecules. Proteins (2015) 0.77
Antibody Recognition of Disordered Antigens. Structure (2015) 0.77
His-tag binding by antibody C706 mimics β-amyloid recognition. J Mol Recognit (2010) 0.77
In vitro neutralization of prions with PrP(Sc)-specific antibodies. Prion (2015) 0.76
X-ray structural and molecular dynamical studies of the globular domains of cow, deer, elk and Syrian hamster prion proteins. J Struct Biol (2015) 0.75
Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression. J Mol Biol (2015) 0.75
The crystal structure of an octapeptide repeat of the prion protein in complex with a Fab fragment of the POM2 antibody. Protein Sci (2013) 0.75
Systems biology of neurodegenerative diseases. Integr Biol (Camb) (2015) 0.75
Coupling of the non-amyloid-component (NAC) domain and the KTK(E/Q)GV repeats stabilize the α-synuclein fibrils. Eur J Med Chem (2016) 0.75